NEW BIOACTIVE PRODUCTS. B-RAF Inhibitors

Transcription

1 B-RAF Inhibitors BAM66400 CHF 5074, 96+% 1mg: $300 A novel, potent and selective small molecule B-Raf kinase BAM66393 GDC-0879, BAM66396 PLX-4032 (RG7204/Vemurafenib/Zelboraf), 96+% BAM66397 PLX-4720, 96+% 2mg: $100; 5mg: $170; 10mg: $270; 25mg: $470 50mg: $360; 100mg: $560; 50mg: $360; 100mg: $560; An B-Raf An B-Raf An B-Raf BAM66392 BAY (Regorafenib), 50mg: $450; 100mg: $750; 200mg: $1200 A multikinase c-kit, VEGFR2, B- Raf BAM66401 BAY (Sorafenib or Nexavar), 1g: $120; 5g: $470 A novel, small molecular of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade

2 VEGFR Inhibitors BAM66392 BAY (Regorafenib), 50mg: $450; 100mg: $7500; 200mg: $1200 A multikinase c-kit, VEGFR2, B-Raf BAM66406 SU11248 (Sunitinib), 96+% A multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase BAM66398 RAF265 (CHIR-265), 10mg: $370; 25mg: $570; 50mg: $970; 100mg: $1670 An oral, highly selective RAF and VEGFR kinase BAM66401 BAY (Sorafenib or Nexavar), 1g: $120; 5g: $470 A novel, small molecular of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade XL184 (Cabozantinib or BMS ), 200mg: $1470 A potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret

3 FLT3 Inhibitors BAM66391 AC220 (Quizartinib), 10mg: $270; 50mg: $670; 200mg: $1770 A uniquely potent and selective FLT3 BAM66406 SU11248 (Sunitinib), 96+% A multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase XL184 (Cabozantinib or BMS ), 200mg: $1470 A potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret

4 KIT Inhibitors BAM66392 BAY (Regorafenib), 50mg: $450; 100mg: $750; 200mg: $1200 A multikinase c-kit, VEGFR2, B-Raf BAM66406 SU11248 (Sunitinib), 96+% A multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase XL184 (Cabozantinib or BMS ), 200mg: $1470 A potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret

5 PARP Inhibitors BAM66402 ABT-888 (Veliparib), 10mg:$99, 25mg:$160, 50mg:$250, 200mg: $745 A potent of both PARP-1 and PARP-2 BAM66403 AG (PF ), 5mg: $120; 10mg: $195; 50mg: $780; 100mg: $1300 A PARP BAM66404 AZD-2281 (Olaparib or KU ), A potent PARP

6 PI3K Inhibitors BAM66395 BKM-120, 5mg: $170; 10mg: $320; 50mg: $870 A bioavailable specific oral panclass I PI3K kinase BAM66394 GS-1101 (CAL-101), 200mg: $1270 A potent PI3K p110d BAM66399 XL147 (SAR245408), 50mg: $370; 100mg: $670; 200mg: $1170 A selective of Class I PI3K isoforms.

7 MET Inhibitors BAM66388 PF (Crizotinib),97+% 50mg: $370; 100mg: $650; Inhibitor of the c-met kinase and the NPM- ALK. XL184 (Cabozantinib or BMS ), 200mg: $1470 A potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret

8 Other Inhibitors BAM66388 BAM66406 PF (Crizotinib),97+% SU11248 (Sunitinib), 96+% BAM66389 AZD-8055, 97+% BAM66407 BAM66401 BMS (Dasatinib or Sprycel), 96+% BAY (Sorafenib or Nexavar), 50mg: $370; 100mg: $650; 10mg: $160; 50mg: $450; 100mg: $750; 200mg: $1300 1g: $120; 5g: $470 Inhibitor of the c-met kinase and the NPM-ALK. A multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase A potent, selective, and orally bioavailable ATP-competitive mtor kinase An ATP-competitive, dual SRC/ABL A novel, small molecular of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade XL184 (Cabozantinib or BMS ), 200mg: $1470 A potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret BAM66405 CHF 5074, 96+% 5mg:$120; 10mg:$240; 50mg:$750 CHF5074 reduced A 42 and A 40 secretion

9 BAM66402 ABT-888 (Veliparib), 10mg:$99, 25mg:$160, 50mg:$250, 200mg: $745 BAM66400 CHF 5074, 96+% 1mg: $300 BAM66393 GDC-0879, BAM66396 PLX-4032 (RG7204/Vemurafenib/Zelboraf), 96+% BAM66397 PLX-4720, 96+% BAM66392 BAM66388 BAY (Regorafenib), PF (Crizotinib),97+% BAM66391 AC220 (Quizartinib), BAM66406 SU11248 (Sunitinib), 96+% BAM66389 AZD-8055, 97+% BAM66403 AG (PF ), 2mg: $100; 5mg: $170; 10mg: $270; 25mg: $470 50mg: $360; 100mg: $560; 50mg: $360; 100mg: $560; 50mg: $450; 100mg: $750; 200mg: $ mg: $370; 100mg: $650; 10mg: $270; 50mg: $670; 200mg: $ mg: $160; 50mg: $450; 100mg: $750; 200mg: $1300 5mg: $120; 10mg: $195; 50mg: $780; 100mg: $1300 A potent of both PARP-1 and PARP-2 A novel, potent and selective small molecule B-Raf kinase An B-Raf An B-Raf An B-Raf A multikinase c-kit, VEGFR2, B-Raf Inhibitor of the c-met kinase and the NPM- ALK. A uniquely potent and selective FLT3 A multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase A potent, selective, and orally bioavailable ATP-competitive mtor kinase A PARP

10 BAM66404 AZD-2281 (Olaparib or KU ), A potent PARP BAM66395 BKM-120, BAM66394 GS-1101 (CAL-101), BAM66399 XL147 (SAR245408), BAM66398 RAF265 (CHIR-265), BAM66407 BAM66401 BMS (Dasatinib or Sprycel), 96+% BAY (Sorafenib or Nexavar), 5mg: $170; 10mg: $320; 50mg: $ mg: $ mg: $370; 100mg: $670; 200mg: $ mg: $370; 25mg: $570; 50mg: $970; 100mg: $1670 1g: $120; 5g: $470 A bioavailable specific oral pan-class I PI3K kinase A potent PI3K p110d A selective of Class I PI3K isoforms. An oral, highly selective RAF and VEGFR kinase An ATP-competitive, dual SRC/ABL A novel, small molecular of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade XL184 (Cabozantinib or BMS ), 200mg: $1470 A potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret BAM66405 CHF 5074, 96+% 5mg:$120; 10mg:$240; 50mg:$750 CHF5074 reduced A 42 and A 40 secretion

11 BAM66388 PF (Crizotinib) XL184 (Cabozantinib or BMS ) BAM66389 AZD-8055 BAM66391 AC220 (Quizartinib) BAM66392 BAY (Regorafenib) BAM66393 GDC-0879 BAM66394 GS-1101 (CAL-101) BAM66395 BKM-120

12 BAM66396 PLX-4032 (RG7204 or Vemurafenib or Zelboraf) BAM66397 PLX-4720 BAM66398 RAF265 (CHIR-265) BAM66399 XL147 (SAR245408) BAM66400 SB BAM66401 BAY (Sorafenib or Nexavar) BAM66402 ABT-888 (Veliparib) BAM66403 AG (PF )

13 BAM66404 AZD2281 (Olaparib or KU ) BAM66405 CHF 5074 BAM66406 SU11248 (Sunitinib) BAM66407 BMS (Dasatinib or Sprycel)